03 Profile
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Respiratory (asthma/COPD)
Sanjay S. Shukla
MD, president and CEO of Atyr
press citation on 1 topic since 3 Nov 2026 · last quoted 3 Nov 2026
02 Quoted on · 1 of 29 topics
Sanjay S. Shukla: key facts
- Kind of voice
- Academic
- Role
- MD, president and CEO of Atyr
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 1
- Most recently quoted
- 3 Nov 2026
04 The signal · where Sanjay S. Shukla sits on respiratory (asthma/copd)
Ranked 51= of 100 voices quoted in the press on respiratory (asthma/copd), level with 49 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Darush Attar-ZadehClinicianExecutive Chair, Primary Care Respiratory Society; Clinical Fellow Respiratory Pharmacist, North West London Integrated Care Board, Primary Care Respiratory Society (PCRS)7
- 1=
Dr Andy WhittamoreClinicianClinical Lead (and practising GP), Asthma + Lung UK7 - 3
Alvar Agusti, MD, PhDAcademicProfessor of Medicine; Chair, GOLD Board of Directors, University of Barcelona / Hospital Clínic de Barcelona5 - 51=Dr Mikaela BloombergAcademicStudy lead, UCL Institute of Epidemiology and Health Care1
- 51=Daniel CulverAcademicMD, chair of the division of pulmonary medicine at the Cleveland Clinic and the study's first author1
- 51=Sanjay S. ShuklaAcademicMD, president and CEO of Atyr1
- 51=Mat CallisterClinicianLead Consultant in Respiratory Medicine at Leeds Teaching Hospitals NHS Trust and Honorary Professor at the University of Leeds1
- 51=Victor SadauskasAcademicMD, founder and CEO of Kivo Health1
Showing the leaders and the ranks around 51=, of 100 voices · See every voice on the topic →
05 On the record · press
What Sanjay S. Shukla has said
- sarcoidosisnews.com1
Where Sanjay S. Shukla has been quoted
- 01Final trial data show pulmonary sarcoidosis drug helps patientssarcoidosisnews.com · 3 Nov 2026
Verbatim
“The improvements across multiple [patient-reported outcomes], together with preserved lung function and a favorable safety profile, reinforce our confidence in efzofitimod's potential and provide a strong foundation for its continued development in pulmonary sarcoidosis”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Positive First ILD Pulmonary Rehabilitation programme for patients in the Omagh, Strabane and Fermanagh areaWestern Health & Social Care Trust
- Americans Are Open to Lung Cancer Screening, but Awareness and Education Have Not Caught UpIpsos
- Hospital trust admits mother’s death from missed pulmonary embolism was avoidable as family receives settlementLeigh Day
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.